Joel Greenblatt’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$253K Buy
+17,318
New +$164K ﹤0.01% 1745
2023
Q3
– Sell
-46,090
Closed -$298K – 1314
2023
Q2
$298K Sell
46,090
-77,174
-63% -$527K 0.01% 1126
2023
Q1
$929K Buy
123,264
+7,162
+6% +$65K 0.02% 770
2022
Q4
$1.18M Buy
116,102
+37,464
+48% +$433K 0.03% 623
2022
Q3
$778K Buy
+78,638
New +$863K 0.02% 736
2022
Q1
– Sell
-28,415
Closed -$406K – 1114
2021
Q4
$406K Sell
28,415
-44,652
-61% -$678K 0.01% 847
2021
Q3
$1.46M Buy
73,067
+47,579
+187% +$841K 0.06% 382
2021
Q2
$561K Buy
+25,488
New +$703K 0.02% 653

Other funds holding ABCL

Joel Greenblatt's ABCL Position: Q3 2026 in Review

Joel Greenblatt opened a new position in AbCellera Biologics (ABCL) in Q3 2026: 17,318 shares worth $253K. The stake represents ﹤0.01% of the portfolio and ranks #1745 among its holdings. This is a return to the name: Joel Greenblatt previously reported a position in ABCL as recently as Q2 2023.

Joel Greenblatt first reported a position in ABCL in Q2 2021 and has held it in 8 quarters since. The position peaked at $1.46M in Q3 2021. 164 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

  • Joel Greenblatt held 17,318 shares of AbCellera Biologics worth $253K as of Q3 2026.
  • AbCellera Biologics was a new Joel Greenblatt position in Q3 2026.
  • AbCellera Biologics made up ﹤0.01% of Joel Greenblatt's portfolio in Q3 2026, its #1745 holding.
  • Joel Greenblatt first reported a position in AbCellera Biologics in Q2 2021 and has held it in 8 quarters since.
  • Joel Greenblatt's AbCellera Biologics position peaked at $1.46M in Q3 2021.
  • 164 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Gotham Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.